Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Moleac's Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards

Moleac Pte Ltd
Posted on: 13 Oct 16

PR Newswire

SINGAPORE, Oct. 13, 2016

SINGAPORE, Oct. 13, 2016 /PRNewswire/ -- NeuroAiDTM has been named New Product Innovation of the Year by Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiDTM's Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held this evening at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.

Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiDTM as the recipient. Its independent panel of judges included senior members across various offices at Frost & Sullivan. The judging panel looked at market performance indicators, including revenue growth, market share, availabilities, geographical expansion and marketing strategies.

Dr. M. Shaillender, Industry Analyst, Healthcare Practice - Asia Pacific at Frost & Sullivan, said, "Stroke rehabilitation is an underserved segment in the pharmaceutical industry. Moleac aims to address the existing gaps in stroke therapy with an unconventional approach similar to 'reverse innovation.' NeuroAiDTM is a product originating from Traditional Chinese Medicine that has demonstrated excellent attributes in post-stroke recovery, however, without any scientific and clinical evidence. Moleac's team was instrumental in identifying and decoding the underlying neuromodulatory properties to translate it into a therapeutic drug supported by clinical evidence for neurological disorders."

He further adds, "As one of the first therapies of its kind, NeuroAiDTM is today accepted as an innovative treatment for post-stroke recovery. It is approved and marketed in over 35 countries as a supplement for stroke rehabilitation. Executing well in its vision, Moleac is on a trajectory to expand the horizons of NeuroAiDTM into a mainstream therapeutic drug for neurological disorders."

David Picard, CEO of Moleac, said, "I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years' anniversary of NeuroAiDTM. Having launched NeuroAiDTM in 2006, we have been focusing our efforts on making NeuroAiDTM available to stroke sufferers around the world. NeuroAiDTM is the first medicine to support stroke recovery, and this is a huge unserved need for millions of suffers. In 2016, over 20,000 patients benefited from NeuroAiDTM worldwide and we aim at making NeuroAiDTM available to more patients in the coming years."

He continued to add, "I would like to thank all those who have contributed to NeuroAiDTM's development over the past 10 years. This includes our academic partners, who have shown interest in our approach enabling its clinical development, our investors who have trusted us, and of course my colleagues who have made this venture a success. Without their support, NeuroAiDTM would not be where it is today. We keep investing in Research with several on-going clinical studies to provide first-class evidences of NeuroAiDTM's benefits in other unserved neurological disorders."

NeuroAiDTM is a natural medicine originating from Traditional Chinese Medicine. In addition to its excellent safety profile, clinical trials have shown that patients taking NeuroAiDTM for 3 months have higher chances to reach functional recovery, with prolonged benefits over the long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects have been included in clinical trials and Moleac is currently supporting additional international clinical trials to demonstrate the potential of NeuroAiDTM in other neurological disorders.

About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itself to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiDTM: NeuroAiDTM is a post-stroke recovery treatment to help stroke survivors achieve a faster and better recovery. Moleac also markets NeuroAiD II, a simplified formula. Both products are shown to be equivalent in pharmacology. It currently reaches out to patients in over 35 countries.

Contact details:

Global Marketing
Moleac Pte Ltd
+65 6211 3710
marketing@moleac.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/moleacs-flagship-product-neuroaid-named-asia-pacific-neurological-disorders-new-product-innovation-of-the-year-at-the-frost--sullivan-best-practices-awards-300344417.html

SOURCE Moleac Pte Ltd

PR Newswire
www.prnewswire.com

Last updated on: 13/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.